6/20/2012 7:22:02 AM
Institutional investors doubt that treatments for Alzheimer's disease being developed by Pfizer Inc and Eli Lilly will achieve the main goals of their ongoing late-stage trials, but hopes are running far higher for the Pfizer drug, according to a survey by ISI Group Inc. Results from the survey of 146 investors were released late on Tuesday by Mark Schoenebaum, a pharmaceutical analyst for the investment research services group. Wall Street is eagerly awaiting results of the trials and expects huge potential sales if either of the medicines proves able to arrest the progression of the memory-robbing disease.
comments powered by